FDA Accepts Depomed, Inc. Drug Filing; Triggers $10 Million Milestone Fee

Reuters -- Depomed Inc said U.S. health regulators accepted the company's marketing application for its experimental pain drug, triggering a $10 million milestone payment from its licensee and sending its shares up 12 percent.